Vericel Corp - Company Profile
Powered by 
All the sales intelligence you need on Vericel Corp in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Vericel Corp fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Vericel Corp.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Vericel Corp (Vericel) is a biopharmaceutical company that develops, markets, and commercializes advanced cell therapy products for sports medicine and severe burn care. Vericel's major products are MACI, an autologous cultured chondrocyte implant for treating knee cartilage defects, and Epicel, a cultured epidermal autograft used in the treatment of severe burns. The company holds an exclusive license for NexoBrid, a biological product for eschar removal in burn care. Vericel's products are sold through sports medicine, orthopedic surgeons, and specialized burn centers through cell therapy specialists in the US. The company collaborates with partners for the commercialization of its products outside the US. Vericel operates manufacturing facilities in the US. Vericel is headquartered in Cambridge, Massachusetts, the US
Headquarters
United States of America
Address
64 Sidney St, Cambridge, Massachusetts, 02139
Website
www.vcel.com
Telephone
1 617 5885555
No of Employees
398
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
VCEL (NASD)
Revenue (2024)
$276.3M
16.5%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
59.4%
(2024 vs 2023)
Market Cap*
$2.3B
Net Profit Margin (2024)
XYZ
36.8%
(2024 vs 2023)
* As of and is in US$
Vericel Corp premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Autologous Cultured Chondrocytes on Porcine Collagen Membrane | MACI |
| Cultured Epidermal Autograft | Epicel |
| Botanical Drug Product Containing Proteolytic Enzymes | NexoBrid |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Regulatory Approval | In August, the company received approval for NexoBrid from the US Food and Drug Administration to treat pediatric patients with thermal burns. |
| 2024 | Regulatory Approval | In August, the company received approval from the U.S. Food and Drug Administration for its application expanding the MACI (autologous cultured chondrocytes on porcine collagen membrane) label to include arthroscopic delivery of MACI to repair cartilage defects of the knee up to 4 cm2 in size. |
| 2022 | Regulatory Approval | In December, the company's NexoBrid received approval from the US Food and Drug Administration for the treatment of severe thermal burns in Adults. |
Competitor Comparison
| Key Parameters | Vericel Corp | Stryker Corp | Zimmer Biomet Holdings Inc | Smith & Nephew Plc | CONMED Corp |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United Kingdom | United States of America |
| City | Cambridge | Portage | Warsaw | Watford | Largo |
| State/Province | Massachusetts | Michigan | Indiana | England | Florida |
| No. of Employees | 398 | 56,000 | 17,000 | 16,988 | 3,900 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Dominick C. Colangelo | Chief Executive Officer; Director; President | Executive Board | 2013 | 62 |
| Joe Mara | Chief Financial Officer | Senior Management | 2021 | 51 |
| Michael Halpin | Chief Operating Officer | Senior Management | 2017 | 64 |
| Roland DeAngelis | Chief Marketing Officer | Senior Management | 2014 | - |
| Sean Flynn | Chief Legal Officer | Senior Management | 2019 | 52 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer